Home/Filings/4/0002050755-25-000015
4//SEC Filing

Hoffman Reid 4

Accession 0002050755-25-000015

CIK 0001817229other

Filed

Oct 14, 8:00 PM ET

Accepted

Oct 15, 6:32 PM ET

Size

13.1 KB

Accession

0002050755-25-000015

Insider Transaction Report

Form 4
Period: 2025-10-10
Transactions
  • Sale

    Common Stock

    2025-10-13$32.36/sh19,672$636,5601,314,120 total
  • Sale

    Common Stock

    2025-10-14$30.32/sh33,668$1,020,7871,278,118 total
  • Sale

    Common Stock

    2025-10-10$30.97/sh40,983$1,269,1331,333,792 total
  • Sale

    Common Stock

    2025-10-13$33.09/sh2,334$77,2261,311,786 total
Hoffman Reid
10% Owner
Transactions
  • Sale

    Common Stock

    2025-10-13$32.36/sh19,672$636,5601,314,120 total
  • Sale

    Common Stock

    2025-10-13$33.09/sh2,334$77,2261,311,786 total
  • Sale

    Common Stock

    2025-10-10$30.97/sh40,983$1,269,1331,333,792 total
  • Sale

    Common Stock

    2025-10-14$30.32/sh33,668$1,020,7871,278,118 total
Footnotes (5)
  • [F1]This transaction was executed in multiple trades at prices ranging from $30.68 to $31.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F2]The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
  • [F3]This transaction was executed in multiple trades at prices ranging from $32.00 to $32.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F4]This transaction was executed in multiple trades at prices ranging from $33.00 to $33.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F5]This transaction was executed in multiple trades at prices ranging from $30.00 to $30.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Issuer

Vor Biopharma Inc.

CIK 0001817229

Entity typeother

Related Parties

1
  • filerCIK 0001519339

Filing Metadata

Form type
4
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 6:32 PM ET
Size
13.1 KB